Trend, participation and relative evidence are sufficiently aligned for selective exposure.
74
technical evidence
out of 100
out of 100
Week Ending: 28 August 2026
United States US Healthcare Industry
Diagnostics & Research
For the week ending 28 August 2026, Diagnostics & Research declined 0.16% with 14 advancing, 29 declining, and 1 unchanged constituents. The index is equal weighted and the constituent tape shows uncapped security returns.
Current architecture
Upward Expansion
The activity fan is positively ordered above a rising Trend Line with price accepted above it.
74
technical evidence
Index1337.72
1 week-0.16%
Breadth32%
Members44
Country
🇺🇸 United States · US
Sector
Healthcare
Universe
NASDAQ, NYSE
Price basis
Adjusted weekly close
Trend architecture
Index, activity fan and structural anchors
Rolling 156-week evidence. Trend Signal points mark weeks when price, trend and the activity fan confirmed together.
Index Value
Trend Line
Fair Value
Activity Lines
Constructive architecture
Transitional architecture
Defensive architecture
Current architecture
Upward Expansion
6 completed weeks in this state
Trend acceptance
23.7%
Index versus Trend Line
Persistence
100%
Positive across every horizon
Participation
32%
14 advancing, 29 declining
Investor positioning lens
Is the evidence ready for capital?
A rules-based technical classification using trend, breadth, persistence, relative strength and path quality.
Evidence balance
Position
Five-pillar map
Trend
82
Breadth
44
Persistence
83
Relative
90
Risk quality
84
What supports the view
- The index remains above a constructive Trend gate.
- Constituent trends show positive multi-horizon persistence.
- Relative performance is improving within its parent hierarchy.
What restrains conviction
- Breadth remains too narrow or inconsistent for a high-conviction position.
- The index is extended well above current Fair Value, increasing chase risk.
- Positive contribution is concentrated in a small leadership cohort.
This is a weekly research classification, not personal investment advice. Sentiment is reported as an independent confirmation layer and does not alter the technical score.
Trend state and durability
Architecture, persistence and constituent regimes
The index path is tested against the underlying security-level trend evidence.
The activity fan is positively ordered above a rising Trend Line with price accepted above it.
State age6 weeks
Trend gateUp
Fan width12.54%
Fast versus slow change2.00 pts
Above 83%
Below 0%
Six completed weeks of price acceptance relative to the full Activity Line fan.
Index persistence
100% agreement
Positive across every horizon
The 13, 26, 39 and 52-week trends all point upward, giving the advance broad horizon agreement.
13-week
23.4%
26-week
27.8%
39-week
10.9%
52-week
43.9%
Constituent trend persistence
91% coverage
Is the index move broadly durable?
75%positive
Coherent positive55%
Coherent negative8%
Average horizon agreement82%
Positive horizon share76%
Weakening positives2
Repairing negatives4
40 constituents measured as of 21 Aug 2026. Median trend age is 20 weeks.
Custom stage map
89% coverage
Where constituents sit in the cycle
44%Stage 2
Stage 1 · Basing23%9 securities
Stage 2 · Advancing44%17 securities
Stage 3 · Distribution18%7 securities
Stage 4 · Declining15%6 securities
Re-acceleration watch0
Transition watch6
Relative strength leaders69%
Fair Value repairs3
Measured as of 21 Aug 2026. Stages summarize price, Activity Line architecture, Fair Value position and relative evidence.
Architecture breadth
77/100 mean confidence
How market energy is distributed
Architecture breadth shows the distribution of expanding, rotating, balancing and contracting securities. It is diagnostic context and is not added as a second vote in the positioning score.
Capital rotation
Performance relative to Healthcare
Relative index
13-week relative trend
Starting level
A rising relative line means this group is compounding faster than Healthcare. A falling line means capital has done better in the parent benchmark.
Relative index182.2
13-week trend167.3
4-week trend change6.15%
Weekly peer rank3 of 11
1 week
1.2 pts
relative
4 weeks
6.2 pts
relative
13 weeks
19.6 pts
relative
26 weeks
24.1 pts
relative
52 weeks
33.6 pts
relative
Market internals
Participation, dispersion and path risk
Equal-weight index evidence with constituent-level breadth and dispersion.
Breadth
Narrow
Participation quality
32%
advanced
- Advancing
- 14
- Declining
- 29
- Unchanged
- 1
Risk and persistence
52-week lens
Path quality
Annualised weekly volatility27.0%
Drawdown from 52-week high-0.2%
Positive weeks, last 1354%
Current directional run1 week
Turnover versus 13-week norm72%
Breadth impulse-26.2 pts
Cross-section
44 measured
Return distribution
Q1 -2.9%
Median -1.3%
Q3 0.7%
Average winner6.1%
Average loser-3.1%
Dispersion6.6 pts
Top-five upside share82%
Top-five capital share60%
Capital data coverage100%
Dispersion describes how far constituent outcomes are spreading apart. Capital concentration is contextual only; the index itself is equal weighted.
Momentum cycle
30-week persistence
Positive readings show expansion. Negative readings show contraction.
Breadth cycle
Net participation
Advancers less decliners as a percentage of measured constituents.
News and narrative
Does company news confirm the market tape?
57out of 100
More positive than negative
Positive company scores outnumber negative ones, but the overall score remains close to 50.
Evidence quality
49/100 confidence
Coverage before conviction
Qualified companies2148% of measured constituents
Articles1677100% direct company evidence
Publishers426Independent sources represented
Latest evidence29 AugFreshness is weighted in the score
Constructive 57%Balanced 38%Cautious 5%
Price confirms news9
Price disagrees7
Negative news absorbed1
Positive but stretched7
Constructive edge
Strongest qualified tone
A76/100 confidence · 103 direct
67
Agilent (NYSE) Expanded Non-GAAP Margin 320 bps. How Much Is Repeatable?
MTD50/100 confidence · 101 direct 62Bank of Nova Scotia Takes $4.22 Million Position in Mettler-Toledo International, Inc. $MTD
NTRA52/100 confidence · 103 direct 61Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
DGX43/100 confidence · 71 direct 61Quest Diagnostics stock edges higher as investors respond to fresh institutional buying and…
IDXX41/100 confidence · 86 direct 61Why Is IDEXX Laboratories (IDXX) Getting Fresh Attention Now?
Narrative risk
Weakest qualified tone
MYGN40/100 confidence · 56 direct
35
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
QGEN48/100 confidence · 73 direct 47Could Qiagen (QGEN) Stock Win as Its FDA Clearance Opens a New Diagnostics Market?
MEDP50/100 confidence · 67 direct 49Medpace (MEDP): Buy, Sell, or Hold Post Q2 Earnings?
VCYT41/100 confidence · 53 direct 52Is it Worth Adding Veracyte Stock to Your Portfolio Now?
TWST43/100 confidence · 93 direct 54Twist Bioscience Corp (TWST) Stock Up 7.5% but GF Value Says Overvalued -- GF Score: 69/100
Only fresh, quality-controlled company evidence is included. Industry and sector context is down-weighted and cannot create a directional group conclusion on its own.
Leadership tape
Leaders, laggards and contribution shape
Latest completed week, ranked on uncapped constituent returns.
Constituent ledger
Industry constituents
All 44 measured constituents, ranked by latest weekly return.
Rank
Ticker
Company
Exchange
Market cap
Close
Index contribution
Return
The index uses capped equal-weight weekly constituent returns. The ledger shows uncapped security returns so outliers remain visible for research.